Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

Memórias do Instituto Oswaldo Cruz

Bianca Zingales¹  Michael A Miles¹  Carolina B Moraes¹  Alejandro Luquetti¹  Felipe Guhl¹  Alejandro G Schijman¹  Isabela Ribeiro¹ 

关键词: in vitro drug screening;    T. cruzi;    genetic diversity;    guidelines;   

DOI  :  10.1590/0074-0276140156

来源: SciELO

【 摘 要 】

This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License